On Thursday, Following U.S. Stocks were among the “Top Gainers”: OXiGENE, Inc. (NASDAQ:OXGN), Integrated Silicon Solution Inc. (NASDAQ:ISSI), BioScrip, Inc. (NASDAQ:BIOS), InspireMD, Inc. (NYSEMKT:NSPR)

OXiGENE Inc(NASDAQ:OXGN), with shares inclined 12.28%, closed at $1.92.

Integrated Silicon Solution, Inc.(NASDAQ:ISSI), with shares jumped 12.01%, settled at $18.56.

BioScrip Inc (NASDAQ:BIOS), with shares climbed 11.76%, and closed at $3.85.

InspireMD Inc(NYSEMKT:NSPR), surged 11.50%, and closed at $0.290.

Latest NEWS regarding these Stocks are depicted underneath:

OXiGENE, Inc. (NASDAQ:OXGN)

OXiGENE, Inc. (OXGN), a clinical-stage biopharmaceutical corporation developing novel therapeutics to treat cancer, will report year-end 2014 results on Tuesday March 17, 2015. A conference call and webcast hosted by OXiGENE administration will start at 4:30 pm ET (1:30 p.m. PT).

OXiGENE’s earnings conference call can be heard live by dialing (888) 841-3431/ Conference ID: 87728293 in the United States and Canada, and +1 (678) 809-1060 for international callers, five minutes preceding to the starting of the call.

OXiGENE is a clinical-stage biopharmaceutical corporation developing novel therapeutics to treat cancer. The corporation is focused on developing vascular disrupting agents (VDAs), which are compounds that selectively disrupt abnormal blood vessels associated with solid tumor survival and progression.

Integrated Silicon Solution Inc. (NASDAQ:ISSI)

Integrated Silicon Solution Inc. (ISSI), a global fabless semiconductor corporation, and a Chinese consortium of investors led by Summitview Capital (the “Consortium”), recently jointly declared that they have reached a definitive merger contract under which the Consortium will attain all of the outstanding shares of ISSI for US$19.25 per share in cash. The projected transaction values ISSI’s equity at about US$639.5 million, on a fully diluted basis. The transaction is subject to approval by the stockholders of ISSI, in addition to antitrust and other regulatory approvals. As part of the transaction, the merger contract contemplates that, in connection with the closing of the merger, ISSI’s operations in Taiwan will be restructured or some or all of ISSI’s Taiwan operations will be sold as necessary to comply with the requirements of Taiwan laws and regulations. The Chinese consortium members also comprise eTown MemTek Ltd., Hua Capital and Huaqing Jiye.

The ISSI Board of Directors has unanimously approved the merger contract and recommends that the ISSI stockholders vote to approve the merger contract. Details regarding the record date, and the date, time and place of the special meeting of stockholders to vote on the transaction will be declared at a later date. The transaction is presently predictable to close in the third calendar quarter of 2015.

With annual proceeds of US$329 million for fiscal 2014, ISSI is a fabless semiconductor corporation that designs and markets high performance integrated circuits for the automotive, industrial, medical, networking, mobile communications, and digital consumer electronics markets.

ISSI is a fabless semiconductor corporation that designs and markets high performance integrated circuits for the following key markets: (i) automotive, (ii) communications, (iii) industrial, and (iv) digital consumer. ISSI’s primary products are high speed and low power SRAM and low, and medium and high density DRAM.

BioScrip, Inc. (NASDAQ:BIOS)

BioScrip, Inc. (BIOS), declared the sale of $62.5 million in Series A Convertible Preferred Stock to Coliseum Capital Administration, LLC and associated funds. The Preferred Stock is convertible into 12,088,975 shares of BioScrip’s ordinary stock at a conversion price of $5.17 per share, which was the closing price of BioScrip’s ordinary stock on the NASDAQ Global Market on March 6, 2015. Dividends on the Preferred Stock will be payable quarterly at an annual rate of 8.5% if paid in cash or 11.5% if accrued. As part of the transaction, BioScrip issued to Coliseum Capital warrants for an aggregate of 3.6 million shares of BioScrip stock. Warrants for 1.8 million shares are exercisable at $5.295 per share and warrants for 1.8 million shares are exercisable at $6.596 per share.

In addition, BioScrip intends to conduct a registered rights offering to allow all of BioScrip’s existing stockholders of record, on a date to be determined by the Board, the non-transferable right to purchase their pro rata share of $20.0 million of Preferred Stock and warrants on the same terms as the accomplished private placement to Coliseum Capital. Coliseum Capital and its associates will not take part in the rights offering. Additional details regarding the anticipated rights offering will be comprised of in the Corporation’s Form S-3, which it intends to file with the Securities and Exchange Commission.

The proceeds from the private placement will be used primarily to reduce BioScrip’s outstanding indebtedness.

BioScrip, Inc. provides home infusion and other home care services, and pharmacy benefit administration (PBM) services in the United States. It operates in two segments, Infusion Services and PBM Services.

InspireMD, Inc. (NYSEMKT:NSPR)

InspireMD, Inc. (NSPR), declared its financial and operating results for the fourth quarter and year ended December 31, 2014.

Recent Operating Highlights:

Commercial

• Initiated a Limited Market Release (LMR) of CGuard.
• Resumed shipping of MGuard Prime into hospital accounts. Certain distribution partners also resumed MGuard Prime restocking with hospital customers following European approval of the manufacturing process changes.

REGULATORY / CLINICAL / PRODUCT DEVELOPMENT

• Declared CE Mark approval for CGuard RX rapid exchange delivery system, a MicroNetTM covered carotid stent technology.
• Stated Six-Month Ultrasound Analysis from the CARENET study, which confirmed widely patent internal and external carotid arteries.
• Successfully accomplished pre-clinical PK study with initial DES candidate with promising results.
• Stated positive trends in mortality in the 30 day results on the 310 patients enrolled in MASTER II, in addition to pooled data from MASTER II, and the 433 patient MASTER I trial accomplished and published in 2012.

FINANCIAL

• Strengthened cash position with the completion of financing on November 7th, 2014, with gross proceeds of $8.1 million and March 9th, 2015 with gross proceeds of $13.7 million.
• Implemented cost containment activities, counting measures to significantly reduce the burn rate throughout 2015.

InspireMD, Inc., a medical device corporation, focuses on the development and commercialization of proprietary MGuard stent platform technology. Its MGuard stent is an embolic protection device based on a protective sleeve, which is constructed out of an ultra-thin polymer mesh and wrapped around the stent.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.